Polychemotherapeutic treatment of patients with metastatic breast cancer
Balázs, M.; Tüske, M.
Acta Medica Hungarica 43(4): 407-411
1986
ISSN/ISBN: 0236-5286 PMID: 3601586 Document Number: 275885
A total of 79 metastatic breast cancer patients were treated with a combination of vincristine, doxorubicin and cyclophosphamide (VDC). In 59% of the patients remission occurred, in 23% the condition did not change, while in 18% progression of the disease was observed. The mean duration of the remission was 11 months. The side-effects did practically not influence the course of the treatment.
Document emailed within 1 workday
Related Documents
Schuurman, J.J.; Bong, S.B.; Einarsson, R. 1996: Determination of serum tumor markers TPS and CA 15-3 during monitoring of treatment in metastatic breast cancer patients Anticancer Research 16(4b): 2169-2172Lück, H.J.; Thomssen, C.; du Bois, A.; Lisboa, B.W.; Untch, M.; Kühnle, H.; Jänicke, F.; Meerpohl, H.G.; Lindner, C.; Konecny, G.; Hecker, D.; Diergarten, K. 1997: Preliminary results of a phase Ii study of epirubicin and paclitaxel as first-line treatment in patients with metastatic breast cancer Seminars in Oncology 24(1 Suppl 3: S13-S16
Murray, J.L.; Macey, D.J.; Grant, E.J.; Rosenblum, M.G.; Kasi, L.P.; Zhang, H.Z.; Katz, R.L.; Riger, P.T.; LeBherz, D.; Bhadkamkar, V. 1995: Enhanced TAG-72 expression and tumor uptake of radiolabeled monoclonal antibody CC49 in metastatic breast cancer patients following alpha-interferon treatment Cancer Research 55(23 Suppl): 5925s-5928s
Kimura, M.; Sano, M.; Tabei, T.; Asaga, T.; Ando, J.; Fujii, H.; Yamamoto, N.; Kurosumi, M. 2005: Study of three-weekly docetaxel and weekly trastuzumab treatment in HER 2-overexpressing metastatic breast cancer patients Gan to Kagaku Ryoho. Cancer and ChemoTherapy 32(3): 335-339
Ohtake, T.; Yasuda, M.; Watanabe, K.; Ito, T.; Ito, J.; Miyamoto, K.; Yoshida, S.; Abe, N.; Ishigame, T.; Ishii, M.; Kimijima, I.; Takenoshita, S. 2009: Efficacy and safety of high-dose toremifene for hormone-responsive advanced or metastatic breast cancer patients with failed prior treatment by aromatase inhibitors Gan to Kagaku Ryoho. Cancer and ChemoTherapy 36(9): 1459-1463
Koyama, H.; Iesato, A.; Fukushima, Y.; Okada, T.; Watanabe, T.; Harada, M.; Ito, T.; Maeno, K.; Mochizuki, Y.; Ito, K.; Amano, J. 2011: A retrospective study of high-dose toremifene treatment for patients with aromatase inhibitor refractory advanced or metastatic hormone receptor-positive breast cancer Gan to Kagaku Ryoho. Cancer and ChemoTherapy 38(7): 1123-1126
Incorvaia, L.; Badalamenti, G.; Rini, G.; Arcara, C.; Fricano, S.; Sferrazza, C.; Di Trapani, D.; Gebbia, N.; Leto, G. 2007: MMP-2, MMP-9 and activin A blood levels in patients with breast cancer or prostate cancer metastatic to the bone Anticancer Research 27(3b): 1519-1525
Allegra, C.J.; Egan, G.F.; Drake, J.C.; Steinberg, S.M.; Swain, S.M. 1988: The treatment of metastatic breast cancer with 5-fluorouracil and leucovorin Advances in Experimental Medicine and Biology 244: 107-112
Svennevig, J.L.; Wennberg, J.E.; Bernstein, O.; Lange, J. 1975: Cytostatic drug combinations in the treatment of metastatic cancer of the breast Tidsskrift for den Norske Laegeforening: Tidsskrift for Praktisk Medicin Ny Raekke 95(32): 1854-1855; 1866
Hayes, D.F.; Henderson, I.C.; Shapiro, C.L. 1995: Treatment of metastatic breast cancer: present and future prospects Seminars in Oncology 22(2 Suppl 5: 5
Moĭseenko, V.M.; Orlova, R.V.; Ermakova, N.A.; Protsenko, S.A. 2000: Treatment with Miltex for metastatic skin lesions in breast cancer Voprosy Onkologii 46(5): 600-603
Klaassen, U.; Seeber, S. 1997: Metastatic breast cancer: treatment with fluorouracil-based combinations Oncology 11(9 Suppl 10: 69-73
Liu, X.; Song, S.; Guan, Z.; Wu, S.; Duan, Y.; Yu, J.; Yang, L. 2002: Capecitabine (xeloda) in the treatment of relapsed and metastatic breast cancer Zhonghua Zhong Liu Za Zhi 24(1): 71-73
Chagpar, A.B. 2007: Insights into the management of locally advanced, inflammatory, and metastatic breast cancer: highlights from the 2007 Louisville Breast Cancer Update Journal of the Kentucky Medical Association 105(11): 559-560
Kashiwagi, S.; Ishihara, S.; Asano, Y.; Kurata, K.; Tauchi, Y.; Tokumoto, M.; Morisaki, T.; Noda, S.; Kawajiri, H.; Takashima, T.; Onoda, N.; Hirakawa, K. 2014: Eribulin chemotherapy after taxane treatment in advanced metastatic breast cancer Gan to Kagaku Ryoho. Cancer and ChemoTherapy 41(12): 1951-1953
Holmes, F.A. 1996: Paclitaxel combination therapy in the treatment of metastatic breast cancer: a review Seminars in Oncology 23(5 Suppl 11: 46-56
Rosset, G.; Barrelet, L.; Alberto, P. 1975: Palliative treatment of metastatic breast cancer with diethyldioxystilbene diphosphate (Honvan) Schweizerische Medizinische Wochenschrift 105(43): 1388-1390
Baltali, Eşmen.; Altundağ, M.Kadri.; Güler, Nüfer.; Ozişik, Y.; Firat, Dçer.; Baran, I.; Tekuzman, Gülten. 2002: Paclitaxel and doxorubicin combination in the first-line treatment of metastatic breast cancer Tumori 88(3): 200-203
Kim, Y.; Takatsuka, Y.; Gotoh, K.; Hasegawa, S.; Aritake, N.; Kan, K.; Fukunaga, M.; Touno, T.; Oozato, H.; Imamoto, H.; Yamazaki, K.; Maruyama, H. 1999: Pharmacological study of weekly docetaxel in patients with metastatic breast cancer Gan to Kagaku Ryoho. Cancer and ChemoTherapy 26(10): 1437-1441
Suwa, H.; Yamaguchi, A.; Taji, T.; Shimizu, H.; Masai, Y. 2019: Analysis of Five Days of Administration of S-1 Followed by a Two-Day Rest in Patients with Metastatic Breast Cancer Gan to Kagaku Ryoho. Cancer and ChemoTherapy 46(3): 453-456